Information Provided By:
Fly News Breaks for October 24, 2018
ILMN
Oct 24, 2018 | 06:53 EDT
Barclays analyst Jack Meehan raised his price target for Illumina to $370 saying the company last night "delivered just what the doctor ordered." The company posted "another strong quarter" as its momentum continues, Meehan tells investors in a post-earnings research note. Further, he believes there is good visibility into the sustainability of mid-teens revenue growth momentum into 2019 driven by population sequencing initiatives, traction with clinical customers, and growth in China. He keeps an Overweight rating on Illumina.
News For ILMN From the Last 2 Days
There are no results for your query ILMN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.